DL-dimyristoylphosphatidylglycerol API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for DL-dimyristoylphosphatidylglycerol API 61361-72-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of DL-dimyristoylphosphatidylglycerol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- DL-dimyristoylphosphatidylglycerol
- Synonyms:
- Dimyristoylphosphatidylglycerol , DMPG
- Cas Number:
- 61361-72-6
- DrugBank number:
- DB11284
- Unique Ingredient Identifier:
- BI71WT9P3R
General Description:
DL-dimyristoylphosphatidylglycerol, identified by CAS number 61361-72-6, is a notable compound with significant therapeutic applications. DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
Indications:
This drug is primarily indicated for: DL-dimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Pharmacodynamics:
DL-dimyristoylphosphatidylglycerol exerts its therapeutic effects through: DL-dimyristoylphosphatidylglycerol is a water soluble phospholipid used to solubilize drugs for injection . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
DL-dimyristoylphosphatidylglycerol functions by: As a phospholipid, DL-dimyristoylphosphatidylglycerol can form a micelle with a hydrophobic core to contain lipophilic drugs while maintaining a hyrophilic outer portion to allow increased solubility of the drug in the aqueous environment of the blood or gastrointestinal tract . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
DL-dimyristoylphosphatidylglycerol belongs to the class of organic compounds known as phosphatidylglycerols. These are glycerophosphoglycerols in which two fatty acids are bonded to the 1-glycerol moiety through ester linkages. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions, classified under the direct parent group Phosphatidylglycerols. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Glycerophospholipids class, specifically within the Glycerophosphoglycerols subclass.
Categories:
DL-dimyristoylphosphatidylglycerol is categorized under the following therapeutic classes: Glycerophosphates, Glycerophospholipids, Lipids, Membrane Lipids, Phosphatidic Acids, Phospholipids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
DL-dimyristoylphosphatidylglycerol is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
